Lumos Pharma Inc reports results for the quarter ended in June - Earnings Summary

Lumos Pharma

01/08/2024 22:41

* Lumos Pharma Inc  LUMO.OQ  reported a quarterly adjusted
loss
of 93 cents​​ per share for the quarter ended in June, higher
than the same quarter last year, when the company reported EPS
of $-1.09.  The mean expectation of five analysts for the
quarter was for a loss of $1.24 per share. Wall Street expected
results to range from $-1.31 to $-1.18 per share.
    * Revenue fell 7.4% to $488.00 thousand from a year ago;
analysts
expected $333.33 thousand. 
    * Lumos Pharma Inc's reported EPS for the quarter was a loss
of 93
cents​.
    * The company reported a quarterly loss of $7.55 million.
    * Lumos Pharma Inc shares had fallen by 19.8% this
quarter and
lost 41.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 83.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Lumos Pharma Inc
is $23.00 
This summary was machine generated from LSEG data August 1 at
09:40 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -1.24          -0.93          Beat
 Mar. 31 2024      -1.18          -1.29          Missed
 Dec. 31 2023      -1.15          -1.17          Missed
 Sep. 30 2023      -1.15          -1.04          Beat